Most Popular
-
1
S. Korea, US clinch 2026-30 defense cost-sharing deal in pre-election push
-
2
Military aircraft evacuating S. Koreans in Lebanon returns home
-
3
Concerns raised over chronic labor shortage at state-run center for digital sex crime victims
-
4
BTS-themed moon jar to be unveiled on Hangeul Day
-
5
Samsung unveils 'personalized AI' for all devices
-
6
1,430 minors investigated for drug offenses from 2018 to 2023: police
-
7
Market uncertain on Korea's October rate cut despite slowed inflation
-
8
Special counsel bill to probe first lady scrapped
-
9
Korean bands get their day in the sun, finally
-
10
Coldplay to celebrate release ‘Moon Music’ with Han River drone show
Prosecutors raided around 10 brokerage houses on Wednesday amid allegations that the firms were involved in short-selling Hanmi Pharmaceutical Co. shares based on leaked information.
Investigators also raided Hanmi's headquarters on Monday on speculation it leaked confidential data before an official regulation filing, which could have resulted in unfair trading of shares on the stock market.
The South Korean drugmaker said last month its license deal on a lung cancer treatment drug with Boehringer Ingelheim was canceled, resulting in a sharp drop of its shares. In July 2015, Hanmi had signed an 850 billion-won ($757 million) agreement with the German pharmaceutical giant to jointly develop and sell the new drug, HM61713.
Prosecutors said raids were carried out at securities firms that engaged in relatively heavy short-sellings of Hanmi shares.
Investigators said they will look deeper into the case and find out if any investors gained profits by predicting the sharp decline of Hanmi shares. (Yonhap)
Investigators also raided Hanmi's headquarters on Monday on speculation it leaked confidential data before an official regulation filing, which could have resulted in unfair trading of shares on the stock market.
The South Korean drugmaker said last month its license deal on a lung cancer treatment drug with Boehringer Ingelheim was canceled, resulting in a sharp drop of its shares. In July 2015, Hanmi had signed an 850 billion-won ($757 million) agreement with the German pharmaceutical giant to jointly develop and sell the new drug, HM61713.
Prosecutors said raids were carried out at securities firms that engaged in relatively heavy short-sellings of Hanmi shares.
Investigators said they will look deeper into the case and find out if any investors gained profits by predicting the sharp decline of Hanmi shares. (Yonhap)
